about
Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization.Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study.Comparison of hospital charge prediction models for colorectal cancer patients: neural network vs. decision tree models.Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic reviewComparative effectiveness of coronary artery bypass grafting and percutaneous coronary intervention for multivessel coronary disease in a community-based population with chronic kidney disease.Effectiveness of β-blockers in heart failure with left ventricular systolic dysfunction and chronic kidney disease.CKD and the risk of incident cancer.Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study.Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial.Cost of cancer clinical trials in elderly patients.Patient income level and cancer clinical trial participation.Incremental costs of prostate cancer trials: Are clinical trials really a burden on a public payer system?American Society of Clinical Oncology policy statement on medicaid reform.The impact of insurance on access to cancer clinical trials at a comprehensive cancer centerTrends in Incidence of Hospitalized Acute Myocardial Infarction in the Cardiovascular Research Network (CVRN).Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.Clinical trial participation among patients enrolled in the Glioma Outcomes Project.Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research.Incremental drug treatment cost in HIV-positive patients in industry-sponsored clinical trials.
P2860
Q30730318-442E031F-0114-4617-AC20-8A692F8A6778Q31021002-50ACA220-D16D-46EF-9565-3599D35E7A31Q33629682-3EAB1E9A-7EAB-4AFC-9C73-EA8E531292FFQ33779885-81A8A06B-D556-4DED-9721-666C31A4E431Q34017377-398307C2-48F4-4285-8789-F801D8C620E9Q34020768-F58D84E2-D941-4D09-95CE-AB808BC94B77Q34259993-42CF2B1C-2193-4A8B-8125-05EFDBEF4073Q35102218-959AF4D4-CD74-45A0-A652-0602FB9F9EC8Q35532487-2AD34799-4AE4-4728-919C-4CE628EA478FQ35688141-9593B957-8566-467A-82DD-9D3A0A1A979FQ36589626-CD25C53B-FC1F-4ADF-A4F6-5C7C184E12B5Q36833759-F9BA2DC4-67D0-4C85-BCFE-35C495BF78C7Q36934359-44E158DC-BA35-4B97-9853-C179EDD0D01BQ37023806-FEC9CBB6-B8C7-4B1B-ACB6-EF49ECCD5E26Q38405209-982F7A15-86EF-426C-AF92-0E6A3A32A24CQ45712910-42F24609-F671-4461-BF6A-3CDAAFAB5B9CQ45972500-3402DDC2-B55B-48BC-B8C2-6EE484AE016DQ47192296-B6879E31-5E11-491A-BC37-4960669253B9Q50121983-B372D506-B55A-42AC-92C5-FAC897D500C4
P2860
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Cost of care for patients in cancer clinical trials.
@en
type
label
Cost of care for patients in cancer clinical trials.
@en
prefLabel
Cost of care for patients in cancer clinical trials.
@en
P2093
P2860
P356
P1476
Cost of care for patients in cancer clinical trials.
@en
P2093
Fehrenbacher L
Fireman BH
Gruskin EP
P2860
P304
P356
10.1093/JNCI/92.2.136
P407
P577
2000-01-01T00:00:00Z